VCYT 30.62 ▲ 1.69% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Veracyte Inc.

    NASDAQ: VCYT · Real-Time Price · USD
    30.62
    0.51 (1.69%)
    At close: Sep 03, 2025, 3:59 PM
    30.63
    0.03%
    Pre-market: Sep 04, 2025, 09:27 AM EDT
    1.69%
    Bid 29.82
    Market Cap 2.41B
    Revenue (ttm) 479.13M
    Net Income (ttm) 26.34M
    EPS (ttm) 0.34
    PE Ratio (ttm) 90.06
    Forward PE 20.77
    Analyst Buy
    Ask 30.98
    Volume 1,118,507
    Avg. Volume (20D) 1,440,254
    Open 30.00
    Previous Close 30.11
    Day's Range 29.87 - 30.76
    52-Week Range 22.61 - 47.32
    Beta 1.97

    About VCYT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VCYT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Veracyte Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +7.04%
    Veracyte shares are trading higher amid the announ... Unlock content with Pro Subscription
    6 months ago
    +0.46%
    Veracyte shares are trading lower. The company reported Q4 financial results.
    news image

    5 days ago · businesswire.com

    Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conf...

    news image

    1 week ago · seekingalpha.com

    Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

    Veracyte's Q2 results show strong revenue growth, margin expansion, and a robust cash position, reinforcing my long-term bullish outlook. Key growth drivers include Decipher's expansion, upcoming prod...

    news image

    1 week ago · businesswire.com

    Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test.

    news image

    1 week ago · zacks.com

    Is the Options Market Predicting a Spike in Veracyte Stock?

    Investors need to pay close attention to VCYT stock based on the movements in the options market lately.

    news image

    1 week ago · zacks.com

    Here's Why Veracyte (VCYT) is a Strong Momentum Stock

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

    news image

    2 weeks ago · zacks.com

    Here's Why Veracyte (VCYT) is a Strong Growth Stock

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

    news image

    3 weeks ago · zacks.com

    VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

    Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.

    news image

    4 weeks ago · seekingalpha.com

    Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

    Veracyte, Inc. (NASDAQ:VCYT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Marc A. Stapley - CEO & Director Phillip G.

    news image

    3 weeks ago · fool.com

    Veracyte (VCYT) Q2 Revenue Jumps 14%

    Veracyte (VCYT) Q2 Revenue Jumps 14%

    news image

    4 weeks ago · zacks.com

    Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

    Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.3 per share a year ago.

    Add to Watchlist